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1. Introduction  
The use of psychostimulants, particularly methylphenidate, to treat Attention 
Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents has 
increased rapidly since the 1990s (Schubert et al. 2010). In the 2000s serious reports on 
cardiovascular adverse drug reactions (ADRs), sudden deaths and psychiatric disorders 
have led the regulatory agencies in Europe and the United States (US) to warn against use of 
psychostimulants in the paediatric population (Schubert et al., 2010). In July 2007, class 
labels were implemented in the product information to reflect more specific information 
about cardiovascular and psychiatric adverse events and long-term suppression of growth 
(European Medicines Agency, 2007, US Food and Drug Administration, 2007). Despite these 
warnings, the number of children treated as well as the amount of psychostimulants 
prescribed per child has steadily increased (Kalverdijk et al., 2008).  
Studies have shown that the use of psychostimulants in children in the Netherlands 
increased 8 times from 1996 to 2006 (Trip et al., 2009) and in Germany with 96% from 2000 to 
2007 (Schubert et al., 2010). From 1994 to 2004 the use of psychostimulants in children 
increased 5 times in Norway (Asheim et al., 2007), and from 1987 to 1996 the use of 
psychostimulants increased 10 times among US children (Zuvekas et al., 2006).  
Information about ADRs from psychostimulants has been reported in several clinical studies 
of short duration, primarily conducted in 6 to 12-year olds boys, particularly in the US 
(Bloch et al., 2009). The majority of ADRs reported in these studies were of the type 
gastrointestinal disorders as well as nervous- and psychiatric disorders, and only few serious 
ADRs were reported (Bloch et al., 2009). In spite of pharmacological treatment of children 
with ADHD being common, this practice has been highly debated among health care 
professionals due to the dilemma of treating children with substances potential for abuse, 
where information about long-term safety aspects is very limited (Bloch et al., 2009). The 
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concerns about safety issues from use of psychostimulants in the paediatric population are 
also due to the many anecdotal reports of serious psychiatric ADRs and sudden deaths that 
have been submitted to the regulatory agencies over recent years (Pringsheim & Steeves, 
2011). Systematic analyses of ADRs reported to national databases are necessary, as these 
databases constitute an important, though underestimated, source of data, especially about 
new, serious and rarely occurring ADRs (Hansen, 1992; Aagaard & Hansen, 2009a). We did 
not locate any studies which systematically have analysed spontaneous reports for 
psychostimulants submitted to national databases compared to data on medicine use in the 
paediatric population.  
The objective of this chapter was to 1) describe trends in prescribing of psychostimulants in 
the Danish paediatric population and 2) characterise spontaneous ADR reports submitted to 
the Danish Medicines Agency (DKMA) over a decade with respect to occurrence, 
seriousness, type and age and gender of the child, reported for psychostimulants.  
2. Methods  
2.1 Design 
We conducted a retrospective analysis of all spontaneous ADR reports for 0-17-year old 
children from 2000 to 2009. Data were obtained from the Danish ADR database and placed 
at the disposal of this study in anonymous form with encrypted person identification. The 
unit of analysis was one ADR. Data on medicine use from each of the stimulants were 
extracted on individual level from the national Danish medicines registry as defined daily 
doses (DDD) per 1000 inhabitants per day and users (number of treated persons per 1000 
inhabitants).  
2.2 Setting 
2.2.1 Danish registry of medicine use 
In only a few countries information about medicine use at the individual level is available, 
Denmark being one of these countries. The Registry of Medicinal Product Statistics is a 
national database covering all outpatient pharmacy-dispensed prescriptions in Denmark.  
The registry was established in 1994 to provide complete statistics on the use of medicines in 
Denmark. Data on prescriptions are registered for each patient via the civil registration 
number. Each prescription record contains the date of purchase, the dispensing pharmacy, 
the prescribing physician and detailed information on the drug dispensed, including 
product name, anatomical therapeutic classification (ATC) system name, dosage, package 
size and formulation. Medicine use is recorded in different ways. In this study we apply the 
defined daily doses (DDD) per 1000 inhabitants and number of users per 1000 inhabitants 
for our analysis. The DDD is defined at the assumed average maintenance dose per day for 
a drug used for its main indication in adults (WHO, 2011).  
2.2.2 Definition of psychostimulants 
A psychostimulants is an agent that causes an increase in functional activity, usually of the 
central nervous system (Howard et al., 2010).  Examples of these kinds of effects may 
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include enhanced alertness, wakefulness, and locomotion, among others. Due to their effects 
typically having an "up" quality to them, stimulants are also occasionally referred to as 
"uppers". Stimulants (analeptics) produce a variety of different kinds of effects by enhancing 
the activity of the central and peripheral nervous systems (Howard et al, 2010).  
In this study we focus on the type of stimulants most frequently prescribed in Denmark, i.e. 
methylphenidate, atoxometine, modafinil and amphetamine derivates in the paediatric 
population. According to the official summary of product information methylphenidate and 
atomoxetine are licensed for treatment of ADHD in children and adolescents from 6 and 8 
years of age respectively. Modafinil and amphetamine derivates are not licensed for use in 
children (Danish Medicines Agency, 2011).  
2.2.3 ADR reporting system 
The reporting of ADRs has been obligatory in Denmark since 1 May 1968. Initially, only 
physicians were covered by the obligation; however, in 1972, dentists and veterinary 
surgeons were also required to report ADRs (Aagaard et al., 2008b). Since 1995, drug 
manufacturers have been obliged to keep registers of suspected and demonstrated ADRs 
and to make these available to the regulatory authorities. Since July 2003, consumers and 
other health care professionals have been able to report ADRs directly to the authorities 
(Aagaard et al., 2008b). An ADR report is defined by the following four criteria, which must 
be included in all reports: (i) information about the patient; (ii) the suspected medicine(s); 
(iii) the presumed ADR(s); and (iv) information about the person making the report. An 
ADR report may contain one or more ADR terms (Aagaard et al., 2008b).  
After receiving the ADR reports, professional staff at the DKMA code and categorize the 
ADRs by degree of seriousness and type of reaction according to the Medical Dictionary for 
Regulatory Activities (MedDRA) terminology (Aagaard et al., 2008b).  
ADR reports are forwarded electronically to the respective pharmaceutical companies, 
which periodically assess the ADR reports received. The results of their assessments are 
reported to the DKMA via periodic safety update reports (PSURs). The Danish ADR 
database contains all spontaneous ADR reports in Denmark, including those reported 
directly to the pharmaceutical companies (Aagaard et al., 2008b).  
2.2.4 Adverse drug reaction (ADR) 
An ADR is defined as “any noxious and unintended response to medicines that occurs at 
doses normally used in humans for the prophylaxis, diagnosis or therapy of diseases” 
(Volume 9, 2009).  
2.2.5 Criteria for seriousness 
Severity of reported ADRs was classified according to the criteria defined in volume 9 of the 
rules governing medicinal products in the European Union guideline (Volume 9, 2009).  
Here serious ADRs are divided into: resulting in death, life-threatening, requiring 
hospitalization or prolongation of existing hospitalization, resulting in persistent or 
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significant disability/incapacity in the reporter’s opinion, a congenital anomaly/birth defect 
and other medically important conditions (Volume 9, 2009).  
Other reactions were classified as being non-serious. 
2.2.6 Anatomical therapeutic chemical (ATC) classification groups 
The ATC system classifies medicinal products according to the primary constituent, organ 
or system on which they act and their chemical, pharmacological and therapeutic properties. 
Medicines are divided into 14 main groups (first level), with one therapeutic subgroup 
(second level). The third and fourth levels are chemical/pharmacological/therapeutic 
subgroups and the fifth level is the chemical substance (WHO ATC index, 2011).  
The extract from the ADR database only provides information according to the trade name of 
those medicinal products that have been reported as causing ADRs. Therefore it was necessary 
to translate manually trade names into generic names at ATC level 5 in the national medicines 
register, and then run the generic form of the medicine name against the ADRs reported.  
2.3 Data extraction 
Prescription data were extracted from the Danish registry of dispensed medicine. We 
extracted information about DDDs per 1000 inhabitants per day and number of persons per 
1000 inhabitants prescribed for psychostimulants among children from 0 to 17-years of age. 
Information about gender was also extracted from the registry. ADR reports submitted to 
the DKMA were placed at the disposal of this study in anonymous form with encrypted 
identification of the medicine user. Data were extracted from the ADR database on 
Microsoft Excel files and the material comprised all ADR reports on children from birth to 
17 years of age reported to the Danish Medicines Agency from 2000 to 2009 for the 
psychostimulants. The unit of analysis was one ADR.  
The Danish ADR database defines five categories of persons who may submit data to the 
database. This article applies this official designation for category of person submitting reports:  
• Lawyer: patient injury insurers and/or law firms  
• Pharmacist: community or hospital pharmacists 
• Physician: general practitioners, physicians and dentists 
• Other health care professional: nurses, pharmaceutical companies, social and health 
care assistants 
• Consumers: patients, patients’ relatives, other members of the public 
Because consumers have had the opportunity to report ADRs in Denmark since 2003, results 
from this category only cover data from the last 6.5 years of the study period.  
3. Results  
3.1 Prescribed psychostimulants, 2000-2009 
Figure 1 displays the annual number of DDD/1000 inhabitant/day and no. of persons/1000 
inhabitants/day for all types of psychostimulants prescribed for children from 0 to 17-years 
of age.  
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From 2000 to 2009 the number of prescribed DDDs/1000 inhabitants/day increased with 1629 
% (from 10.87 to 187.97 DDD/1000/inhabitants/day) and the number of treated persons/1000 
inhabitants/day increased with 775 % (from 21 to 183.67 DDD/1000/inhabitants/day).  
From 2000 to 2004 the level of prescribing was rather constant, however from 2005 and 
onwards large increases in the prescribing of psychostimulants were observed. 
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Fig. 1. Annual number of DDDs/1000 inhabitants/day and number of persons/1000 
inhabitants/day for psychostimulants for children from 0 to 17-years of age, (2000-2009) 
Table 1 displays DDDs per 1000 inhabitant/year per category of psychostimulant medications 
from 2000 to 2009. Methylphenidate was the dominant prescribed psychostimulant followed 
by atomoxetine. Only few children and adolescents were prescribed products containing 
amphetamine derivates and modafinil.  
From 2000 to 2009 the number of prescribed DDDs/1000 inhabitants/day increased with 
1557% for methylphenidate (from 10.69 to 177.16 DDD/1000/inhabitants/day), and for 
atomoxetine an increase in DDDs of 1274% was observed (from 0.74 to 10.17 DDD/1000/ 
inhabitants/day). 
 
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Amphetamine 
derivates 
0.17 0.18 0.15 0.18 0.3 0.3 0.36 0.44 0.41 0.3 
Atomoxetine 0 0 0 0 0 0 0.74 4.03 7.17 10.17 
Methylphenidate 10.69 12.79 16.73 20.79 31.09 44.89 61.97 75.77 122.46 177.16 
Modafinil 0 0.06 0.22 0.32 0.33 0.25 0.18 0.24 0.31 0.25 
Table 1. Annual number of DDD/1000 inhabitants/day by psychostimulants for children 
from 0 to 17-years of age, (2000-2009) 
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Figure 2 displays the annual distribution of prescribed DDDs/1000 inhabitants/day for 
methylphenidate by gender. The majority, 80% of DDDs were prescribed in boys.  
From 2000 to 2009 the use of psychostimulants in boys increased with a factor 16 (from 18.92 
to 294.45) and in girls with a factor 32 (from 2.39 to 76.03 DDD/1000 inhabitants/day).   
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Fig. 2. Annual distribution of DDDs/1000 inhabitants/day for methylphenidate by gender, 
2000 - 2009. 
 
0
10
20
30
40
50
60
70
80
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Year
N
o
 o
f 
A
d
v
er
se
 d
ru
g
 r
ea
ct
io
n
s
Amphetamine derivates
Atomoxetine
Methylphenidate
Modafinil
 
Fig. 3. Annual number of adverse drug reactions (ADRs) reported for psychostimulants in 
children, 2000 -2009 
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3.2 Reported adverse drug reactions for psychostimulants, 2000-2009  
From 2000 to 2009 a total of 130 ADR reports including 329 ADRs were reported for 
psychostimulants for individuals from birth to 17 years of age. One half of ADRs were 
serious (N = 165), and no fatal cases were reported. 
Figure 3 displays the annual number of reported ADRs by type of psychostimulant. The 
majority of the ADRs were reported for methylphenidate (N = 251) and atomoxetine (N = 69). 
Only few ADRs were reported for amphetamine derivates (N = 2) and modafinil (N = 7).  
3.2.1 Adverse drug reactions by type of reporter   
The distribution of ADRs reported for psychostimulants by seriousness and type of reporter 
is displayed in table 2.  
Seventy-six percent of ADRs were reported by physicians, 13% of ADRs by consumers and 
10% of ADRs were reported by other health care professionals.  
 
Type of reporter Physician OHCP* Consumer Total  
Amphetamine derivates 2(1) 0 0 2(1) 
Atomoxetine 68(31) 0 1(0) 69(31) 
Methylphenidate 190(71) 31(25) 30(30) 251(126) 
Modafinil 7(7) 0 0 7(7) 
Total 267(110) 31(25) 31(30) 329(165) 
*: OHCP: other health care professionals  
Table 2. Total number of adverse drug reactions (ADRs) distributed by type of reporter, 
medication and criteria of seriousness (in parentheses), 2000-2009 
3.2.2 Adverse drug reactions by age and gender  
Table 3 shows the distribution of ADRs reported for psychostimulants by age, gender and 
seriousness in the paediatric population, 2000-2009.  
Totally, 80 % of ADRs were reported for boys and 20 % of ADRs for girls.  
The largest number of ADRs (N = 75) were reported in 9 to 10-year-olds, followed by 16 to 
17-year olds ( N = 33) and 15 to 16-year olds (N = 32). Less than one percent of ADRs was 
reported in children up to 4 years of age.   
The largest number of ADRs was reported in 9 to 10-year old boys (N = 68). In 16-17 –year 
olds girls, a larger number of ADRs (N = 20) were reported than in boys.  In the age group a 
number of ADR reports were submitted without information about gender.  
Approximately 50% of ADRs reported for both boys and girls were serious, however large 
variations were observed within age groups.  
Table 4 shows the distribution of reported ADRs by gender and type of psychostimulant.   
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Age groups (Y) Boys Girls NA* Total 
<1 0 0 0 0 
1<2 0 0 0 0 
2<3 0 0 0 0 
3<4 0 0 0 0 
4<5 1(0) 0 0 1(0) 
5<6 6(2) 0 0 6(2) 
6<7 18(13) 0 0 18(13) 
7<8 10(5) 4(0) 3(0) 17(5) 
8<9 21(7) 4(3) 0 25(10) 
9<10 68(42) 7(0) 0 75(42) 
10<11 14(1) 0 0 14(1) 
11<12 20(6) 1(0) 0 21(6) 
12<13 19(9) 1(0) 0 20(9) 
13<14 23(16) 3(0) 0 26(16) 
14<15 16(5) 5(3) 0 21(8) 
15<16 24(10) 8(6) 0 32(16) 
16<17 13(8) 20(15) 0 33(23) 
17<18 18(10) 2(0) 0 20(10) 
Total 271(134) 55(31) 3(0) 329(165) 
*: ADR reports without information about gender.  
Table 3. Total number of reported ADRs by age group and gender, serious ADRs in 
parentheses, 2000 - 2009 
 
Medicines Boys Girls NA Total 
Amphetamine derivates 1(1) 1 0 2(1) 
Atomoxetine 48(22) 21(9) 0 69(31) 
Methylphenidate 221(110) 34(23) 3(0) 258(133) 
Modafinil 7(7) 0 0 0 
Total 271(134) 55(31) 3(0) 329(165) 
Table 4. Distribution of total number of reported ADRs (N) by gender and medication 
(numbers of serious ADRs in parentheses), 2000 - 2009  
Approximately 85% of ADRs were reported in boys, the majority for methylphenidate and 
atomoxetine. All ADRs reported for modafinil occurred in boys and they were all serious. 
For amphemine derivates one out of 2 reported ADRs occurred in boys.  
Approximately 45% of ADRs occurring in boys reported for atomoxetine and 
methylphenidate were serious.  
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3.2.3 Adverse drug reactions by type and seriousness 
Table 5 displays the characteristics of ADRs reported for psychostimulants by type, system 
organ class, seriousness and medication.  
The largest share of reported ADRs was of the type “psychiatric disorders” (21 % of total 
ADRs) followed by the SOCs “general disorders” (19% of total ADRs) and “nervous system 
disorders” (16% of total ADRs).  
For ADRs of the type nervous- and psychiatric disorders the share of serious ADRs ranged 
from approximately 50 to 70 % of total ADRs. For the medications atomoxetine and 
methylphenidate approximately 45% of all reported ADRs were serious, and for modafinil 
all reported ADRs were serious.  
 
System Organ Class (SOC) 
(alphabetical order)  
Amphetamine 
derivates 
Methylphenidate Atomoxetine Modafinil Total 
Blood and lymphatic system 
disorders 
0 2(2) 0 0 2(1) 
Cardiac disorders 0 11(4) 6(3) 0 17(7) 
Congenital, familial and genetic 
disorders 
0 0 1(1) 0 1(1) 
Ear and labyrinth disorders 0 1 0 0  1(0) 
Endocrine disorders 0 0 2(2) 0 2(2) 
Eye disorders 0 6 0 0 6(0) 
Gastrointestinal disorders 1 22(12) 10(2) 1(1) 34(15) 
General disorders 0 55(15) 5(2) 0 60(17) 
Infections and infestations 0 0 1(1) 0 1(1) 
Investigations 0 13(10) 7(3) 0 20(13) 
Metabolism and nutrition disorders 0 7(1) 3 0 10(1) 
Musculoskeletal disorders 0 6(3) 1 0 7(3) 
Nervous system disorders 0 48(33) 4(3) 3(3) 55(39) 
Psychiatric disorders 1(1) 48(32) 21(12) 3(3) 73(48) 
Renal and urinary disorders 0 3(1) 1 0 4(1) 
Reproductive system and breast 
disorders 
0 1 0 0 1(0) 
Respiratory disorders 0 4(2) 1 0 5(2) 
Skin and subcutaneous tissue 
disorders 
0 19(5) 3(1) 0 22(6) 
Surgical and medical procedures 0 0 1 0 1(0) 
Vascular disorders 0 5(2) 2(1) 0 7(3) 
Total 2(1) 251(126) 69(31) 7(7) 329(165) 
Table 5. Total number of reported ADRs (N) for children distributed by System Organ Class 
(SOC), medication (serious ADRs in parentheses), 2000-2009  
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Table 6 shows characteristics of ADRs reported for the SOC “psychiatric disorders” by type 
of medication and seriousness.  
 
Adverse drug reaction (ADR) 
(alphabetical order) 
Amphetamine 
derivates 
Methylphenidate Atomoxetine Modafinil Total 
Affect lability 0 3(3) 0 0 3(3) 
Agitation 0 2(1) 0 0 2(1) 
Aggression 0 1 2 1(1) 4(1) 
Anger 0 0 2(1) 0 2(1) 
Animal phobia 0 1(1) 0 0 1(1) 
Anxiety 0 6(2) 2(2) 0 8(4) 
Asocial behaviour 0 1 0 0 1 
Communication disorder 0 1(1) 0 0 1(1) 
Confusional state 0 2(1) 0 0 2(1) 
Depression 0 4(3) 4(1) 0 8(4) 
Drug abuse 0 2(2) 0 0 2(2) 
Emotional disorder 0 1 0 0 1 
Euphoric mood 0 2(2) 0 0 2(2) 
Food aversion 0 0 1(1) 0 1(1) 
Hallucination 0 2(2) 0 1(1) 3(3) 
Impulse-control disorder 0 0 1 0 1 
Insomnia 0 3(2) 0 0 3(2) 
Intentional self-injury 0 0 1(1) 0 1(1) 
Mood swings 0 0 1(1) 0 1(1) 
Nightmare 0 0 1 1(1) 2(1) 
Obsessive thoughts 0 0 1(1) 0 1(1) 
Psychotic disorder 1(1) 0 1(1) 0 2(2) 
Personality change 0 1(1) 0 0 1(1) 
Restlessness 0 1(1) 0 0 1(1) 
Sleep disorder 0 7(5) 1(1) 0 8(6) 
Social avoidant behaviour 0 3(3) 0 0 3(3) 
Suicidal ideation 0 1(1) 3(2) 0 4(3) 
Tic 0 2  0 0 2 
Total 1(1) 46(33) 21(12) 3(3) 73(48) 
Table 6. Total number of reported ADRs of the type “psychiatric disorders” by medication, 
and seriousness (in parentheses), 2000-2009.  
Two-third of ADRs was reported for amphetamine derivates and methylphenidate, and the 
most frequently reported ADRs were anxiety, depression, and sleep disorders.  
Table 7 displays the characteristics of ADRs reported for the SOC “nervous system 
disorders” by type of medication and seriousness.  
Within this SOC approximately 90% of ADRs were reported for methylphenidate, the 
majority of reactions being dizziness, headache and dyskinesia.   
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Adverse drug reaction (ADR) Amphetamine
derivates 
Methylphenidate Atomoxetine Modafinil Total 
Akathisia 0 1(1) 0 0 1(1) 
Atypical benign partial epilepsy 0 0 1(1) 0 1(1) 
Burning sensation 0 2 0 0 2 
Cataplexy 0 0 0 1(1) 1(1) 
Crying 0 2(1) 0 0 1(1) 
Demyelination 0 2(2) 0 0 2(2) 
Disturbance in attention 0 1(1) 0 0 1(1) 
Dizziness 0 8(5) 1(1) 1(1) 10(7) 
Dyskinesia 0 2(2) 0 0 2(2) 
Dystonia 0 1(1) 0 0 1(1) 
Epilepsy 0 2(1) 0 0 2(1) 
Headache 0 12(9) 2(1) 0 14(10) 
Hemiparesis 0 2(2) 0 0 2(2) 
Hypoaesthesia 0 3(2) 0 0 3(2) 
Hypotonia 0 0 0 1(1) 1(1) 
Loss of consciousness 0 2(1) 0 0 2(1) 
Nystagmus 0 1 0 0 1 
Psychomotor hyperactivity 0 2(1) 0 0 2(1) 
Restless legs syndrome 0 1 0 0 1 
Somnolence 0 1(1) 0 0 1(1) 
Speech disorder 0 2(2) 0 0 2(2) 
Syncope 0 1(1) 0  0 1(1) 
Total 0 48(33) 4(3) 3(3) 55(39) 
Table 7. Total reported ADRs of the type “nervous system disorders” by medication, and 
seriousness (in parentheses), 2000-2009.  
Table 8 shows the characteristics of ADRs reported for the SOC “general disorders and 
administration site conditions” by type of medication and seriousness.   
Within this SOC almost all ADRs were reported for amphetamine derivates, and no ADRs 
were reported for atomoxetine and modafinil. Many ADRs relating to the efficacy of the 
medications were reported.  
A large number of ADRs within the SOC “gastrointestinal disorders” were also reported 
(see table 5). These reactions were predominantly reported for methylphenidate, and were 
of the type’s abdominal pain, diarrhoea and dry mouth (data not shown).  
4. Discussion 
This is the first study from a national ADR database that has examined the characteristics 
and occurrence of ADRs from use of psychostimulants in the paediatric population. The 
study showed that over a decade the prescribing of psychostimulants in the Danish 
paediatric population has increased dramatically, and that methylphenidate was the 
predominant psychostimulant. Two third of ADRs were reported by physicians, and 
approximately 80 % of all ADRs were reported for boys from above 5 years of age. The  
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Adverse drug reaction (ADR) Amphetamine
derivates
Methylphenidate Atomoxetine Modafinil Total 
Asthenia 0 2(2) 0 0 2(2) 
Chest pain 0 5(2) 0 0 5(2) 
Chills 0 1 0 0 1 
Drug effect decreased 0 17(1) 0 0 19(1) 
Drug effect increased 0 1 0 0 1 
Drug ineffective 0 14(2) 0 0 14(2) 
Drug interaction 0 1(1) 1(1) 0 2(2) 
Face oedema 0 1 0 0 1 
Feeling hot 0 1 0 0 1 
Fatigue 0 7(6) 3(1) 0 10(7) 
Irritability 0 0 1 0 1 
Pain 0 1(1) 0 0 1(1) 
Pyrexia 0 1 0 0 1 
Therapeutic response unexpected 
with drug substitution 
0 3 0 0 3(0) 
Total 0 55(15) 5(2) 0 60(17) 
Table 8. Total number of reported adverse drug reactions of the type “general disorders and 
administration site conditions” by medication, and seriousness (in parentheses), 2000-2009.  
largest shares of reported ADRs was of the type “general disorders and administration 
conditions”; “psychiatric and nervous system disorders”.    
From 2000 to 2009 large increases in number of prescribed dosages and users were observed, 
and these findings were in line with results from other countries (Asheim et al. 2007; 
Kalverdijk et al., 2008; Trip et al., 2009; Schubert et al, 2010; Zuvekas et al., 2006). The majority 
of users were boys; but we found a large increase in use of psychostimulants among girls, and 
this pattern was expected (Hodgkins et al, 2011). From 2000 to 2004 the use of 
psychostimulants were at a stable level, however from 2005 the use has increased dramatically. 
Explanations of this increase could be the marketing pressure, change in diagnostic criteria 
and the development of new types of psychostimulants such as atomoxetine and modafinil for 
treatment of ADHD. In the same period of time the pharmaceutical companies have marketed 
long-term release formulations of methylphenidate for school use (van den Ban et al, 2010). 
Use of psychostimulants in Danish children has increased more over the last decade than in 
other countries; however this may be explained by the fact that use of psychostimulants in 
Denmark was lower at the beginning of the period than in other countries.  
This is a descriptive study, and therefore we cannot conclude whether ADRs are reported 
more commonly for methylphenidate than the other products, neither whether girls 
experience more ADRs than boys. The number of ADR reports does not reflect the use of 
psychostimulants, and the question is where in the lifecycle of medicinal products ADRs are 
reported. However, since the issue is long-term treatment of children and adolescents ADR 
signals are extremely important. A high number of reports on decreased drug effect and/or 
ineffective drugs from use of methylphenidate were reported. Whether this signal is due to 
problems with the quality of generic products or that real life is different from the testing 
conditions (Hansen, 1992).  
The majority of reports were submitted by physicians, however, we would also have expected 
a larger number of reports from parents, as they should be concerned about administration 
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medications to their children, especially medications for long-term use, where information 
about long-term effects are limited. The explanation of the large number of reports from 
physicians could be that the parents have become aware of the ADRs, and asked their 
physician to report them. To increase knowledge about ADRs from long term use of 
psychostimulants the number of reports submitted to the Danish Medicines Agency and 
probably other medicines agencies should be increased and the regulatory authorities must 
focus on increasing ADR reporting rates from both health care professionals and consumers.    
An empirical study showed that the licensing material for methylphenidate provided 
minimal evidence on efficacy and safety in children (Aagaard et al. 2009b), and no 
information about long-term safety aspects was reported. Spontaneous reports are an 
important source of information about new and previously unrecognized ADRs, and the 
value of spontaneous reporting schemes lies in their ability to act as hypothesis-generating 
signals. Due to the low number of ADRs reported for psychostimulants in Denmark it is 
necessary to conduct further studies to explore data about rare and serious ADRs in larger 
databases, such as the EU database EudraVigilance and the international WHO-ADR 
database Vigibase (Aagaard et al, 2010). These databases contain large amounts of data 
submitted from European and global populations, and are therefore suitable for studying 
specific ADRs or new signals.  
The strength of our study is that data comprised psychostimulant prescriptions and all 
ADRs reported in one country over a decade. The purpose was to analyse information 
reported to the Danish ADR database on ADRs in the paediatric population from use of 
psychostimulants in the treatment of ADHD, and not to calculate the incidence of ADRs in 
this population as this is not feasible in material based on spontaneous reporting.  
A major limitation to this study is that we do not know to which extent the causality of these 
ADRs can be confirmed, and this has implications for the interpretation of the results. 
Spontaneous reporting systems suffer from different barriers, such as incomplete 
recognition of ADRs, administrative barriers to reporting, and low data quality, all of which 
may result in the underreporting of important serious and rare events. Nonetheless, the 
study provides information on reported ADRs, and this information contributes to 
broadening the knowledge base on psychostimulants safety.  
5. Conclusion  
In Denmark, a large increase in the use of psychostimulants in the paediatric population has 
been observed. The large number of serious reported ADRs indicate that psychostimulants 
should be prescribed with caution of that greater care is needed in relation to prescribing these 
medications for children. The Danish Medicines Agency should monitor prescribing patterns 
more tightly to identify potential risks in the paediatric population in relation to the evolving 
utilisation of use of psychostimulants among children and adolescents and related risks.  
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